IVCVSep 10, 2021

Medulloblastoma Tumor Classification using Deep Transfer Learning with Multi-Scale EfficientNets

arXiv:2109.05025v113 citations
Originality Incremental advance
AI Analysis

This work addresses the problem of tedious and variable manual diagnosis for pathologists in childhood brain tumor classification, though it is incremental as it builds on existing CNN and transfer learning methods.

The authors tackled automated classification of medulloblastoma tumor histological subtypes using deep transfer learning with multi-scale EfficientNets, achieving an F1-Score of 80.1% on a dataset of 161 cases.

Medulloblastoma (MB) is the most common malignant brain tumor in childhood. The diagnosis is generally based on the microscopic evaluation of histopathological tissue slides. However, visual-only assessment of histopathological patterns is a tedious and time-consuming task and is also affected by observer variability. Hence, automated MB tumor classification could assist pathologists by promoting consistency and robust quantification. Recently, convolutional neural networks (CNNs) have been proposed for this task, while transfer learning has shown promising results. In this work, we propose an end-to-end MB tumor classification and explore transfer learning with various input sizes and matching network dimensions. We focus on differentiating between the histological subtypes classic and desmoplastic/nodular. For this purpose, we systematically evaluate recently proposed EfficientNets, which uniformly scale all dimensions of a CNN. Using a data set with 161 cases, we demonstrate that pre-trained EfficientNets with larger input resolutions lead to significant performance improvements compared to commonly used pre-trained CNN architectures. Also, we highlight the importance of transfer learning, when using such large architectures. Overall, our best performing method achieves an F1-Score of 80.1%.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes